Skip to main content
. 2023 Dec 18;102(2):e207948. doi: 10.1212/WNL.0000000000207948

Figure 2. Mean Annual Change in Areal LS BMD Z Score in Glucocorticoid-Exposed Patients With DMD Treated With Bisphosphonates.

Figure 2

ALN = Alendronate; BMD = Bone mineral density; DFZ = Deflazacort; DMD = Duchenne muscular dystrophy; LS = Lumbar spine; NA = Not applicable; NER = Neridronate; NR = Not reported; PAM = Pamidronate; PCS = Prospective cohort study; PDN = Prednisone; PRED = Prednisolone; RCS = Retrospective cohort study; RCT = Randomized controlled trial; RIS = Risedronate; ZLN = Zoledronate. * Statistically significant change.